Cancer is listed as the number one cause of death in Taiwan since 1982. In 2016, cancer represented 27.7% of the cause of all death of the nation. In view of such epidemiological data, cancer has long been recognized as the important disease and issue for public health.
The National Institute of Cancer Research (NICR), promoted from the formerly Division of Cancer Research in 2006, is the first Division and Institute at the NHRI. Since inception, it has established co-operative ties to explore novel and comprehensive clinical trials, and implement translational research derived from the laboratory.
The research themes of NICR focus and launch into disease-oriented translational study programs: the locally prevalent betel nut-associated oral cancer and the less noticeable, devastating pancreatic cancer. The NICR is tasked to integrating and coordinating basic and clinical research to facilitate the development of innovative strategies for the prevention, diagnosis and treatment of prevalent cancers in Taiwan. These missions are consolidated through a platform consisting of basic scientific research in the lab, early-phase clinical trials and companion translational research in cooperative Phase I Unit in National Cheng Kung University Hospital (NCKUH), and large-scale, multicenter studies coordinated by the Taiwan Cooperative Oncology Group (TCOG). TCOG has also involved in clinical investigator developing programs for junior medical faculty staff (the Paul Carbone Academia) in Taiwan and assisted the Health Authority to perform the cancer hospitals accreditation and core measurement to facilitate the quality of cancer patient care in Taiwan.